Julie C. Yates

Julie C. Yates

Auto-generated profile, based on publicly available information

Julie C. Yates

COPD foundation, Miami, FL, United States

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2023 in Chest
Verified
Journal Article
Open access
IBIsaac N. Biney
Isaac N. Biney
Arzu AriArzu Ari
Arzu Ari
IBIgor Z. Barjaktarevic
Igor Z. Barjaktarevic
BCBrian Carlin
Brian Carlin
DCDavid C. Christiani
David C. Christiani
RDRajiv Dhand
Rajiv Dhand
Nebulizers are commonly employed for inhaled drug delivery. As they deliver medication through aerosol generation, clarification is needed on what constitutes safe aerosol delivery in infectious respiratory disease settings. The coronavirus disease 2019 pandemic highlighted the importance of understanding the safety and potential risks of aerosol-generating procedures. However, evidence supporting the increased risk of disease transmission with nebulized treatments is inconclusive, and inconsistent guidelines and differing opinions have left uncertainty regarding their use. Many clinicians opt for alternative devices, but this practice could negatively impact outcomes, especially for patients who may not derive full treatment benefit from hand-held inhalers. Therefore, it is prudent to develop strategies that can be used during nebulized treatment to minimize the emission of fugitive aerosols, these comprising bioaerosols exhaled by infected individuals and medical aerosols generated by the device that may also be contaminated. This is particularly relevant for patient care in the context of a highly transmissible virus. The COPD Foundation Nebulizer Consortium (CNC) was formed in 2020 to address uncertainties surrounding administration of nebulized medication. The CNC is an international, multidisciplinary collaboration of patient advocates, pulmonary physicians, critical care physicians, respiratory therapists, clinical scientists, and pharmacists from research centers, medical centers, professional societies, industry, and government agencies. The CNC developed this Expert Guidance to inform the safe use of nebulized therapies for patients and providers and to answer key questions surrounding medication delivery with nebulizers during pandemics or when exposure to common respiratory pathogens is anticipated. CNC members reviewed literature and guidelines regarding nebulization and developed two sets of guidance statements: one for the health care setting, and one for the home environment. Future studies need to explore the risk of disease transmission with fugitive aerosols associated with different nebulizer types in real patient-care situations and to evaluate the effectiveness of mitigation strategies.

1 October 2006 in Chest
Verified
Journal Article
Open access
GFGary T. Ferguson
Gary T. Ferguson
PCPeter M. Calverley
Peter M. Calverley
JAJulie A. Anderson
Julie A. Anderson
BCBartolome Celli
Bartolome Celli
CJChristine Jenkins
Christine Jenkins
NPNeil Pride
Neil Pride
THE TOWARDS A REVOLUTION IN COPD HEALTH (TORCH) STUDY: FLUTICASONE PROPIONATE/SALMETEROL IS WELL TOLERATED IN PATIENTS WITH COPD OVER 3 YEARS

1 October 2006 in Chest
Verified
Journal Article
Closed access
PJPaul W. Jones
Paul W. Jones
PCPeter M. Calverley
Peter M. Calverley
BCBartolome Celli
Bartolome Celli
JAJulie A. Anderson
Julie A. Anderson
GFGary T. Ferguson
Gary T. Ferguson
NPNeil Pride
Neil Pride

1 October 2006 in Chest
Verified
Journal Article
Open access
BCBartolome Celli
Bartolome Celli
PCPeter M. Calverley
Peter M. Calverley
JAJulie A. Anderson
Julie A. Anderson
GFGary T. Ferguson
Gary T. Ferguson
CJChristine Jenkins
Christine Jenkins
NPNeil Pride
Neil Pride
THE TOWARDS A REVOLUTION IN COPD HEALTH (TORCH) STUDY: FLUTICASONE PROPIONATE/SALMETEROL REDUCES THE RATE OF EXACERBATIONS OVER 3 YEARS

9 February 2024 in JMIR Formative Research
Verified
Journal Article
Open access
KPKerri A Pierz
Kerri A Pierz
NLNicholas Locantore
Nicholas Locantore
GMGretchen McCreary
Gretchen McCreary
RCRobert J Calvey
Robert J Calvey
NHNickole Hackney
Nickole Hackney
JYJulie Yates
Julie Yates
Background: Wellinks is a remote disease management solution that provides novel chronic obstructive pulmonary disease (COPD) care delivery. Objective: This study evaluated the satisfaction, engagement, and clinical outcomes of Wellinks participants. This study also investigated the cadence of health coaching for patients with COPD. Methods: A 24-week interventional study was conducted by Wellinks and the COPD Foundation in 2022. Adults with COPD were recruited by the COPD Foundation in the United States and determined to be eligible if they had phone and internet access, owned a smartphone, and were not currently participating in pulmonary rehabilitation. All study participants provided written informed consent. The Wellinks solution included remote health coaching, pulmonary rehabilitation, and group education; participants were provided the Wellinks app and smart spirometry and pulse oximetry devices. Participants were offered 6 coaching sessions in the first 12 weeks. For the second 12-week period, participants either reduced frequency or discontinued coaching; all other components of the Wellinks solution remained unchanged. The COPD Self-Efficacy Scale, Modified Medical Research Council dyspnea scale, pulmonary function, pulse oximetry, and patient-reported healthcare resource utilization were the clinical outcome measures. Nonclinical outcomes included engagement and satisfaction with Wellinks and net promoter score. Results: In total, 141 adults consented and completed Wellinks onboarding; 84.4% (n=119) of whom remained engaged throughout the 24-week study. Participants had a mean age of 70 (SD 7.8; range 48-88) years, and 55.7% (n=78) were female. Most participants (n=119, 84.4%) completed all 6 coaching sessions during the first 12-week period. Compliance with spirometer and pulse oximeter use was 82.3% and 89.4%, respectively, at week 1 but waned over the study period to 8.5% and 9.2%, respectively, at the end of the study. Participants indicated a high degree of satisfaction with Wellinks, with 95.5% (n=85) and 91% (n=81) of participants indicating that they agreed or strongly agreed that the educational content and health coaching, respectively, were valuable. At the end of the study, the net promoter score was +64 and +55 in the coaching continuation and discontinuation arms, respectively. A significant improvement from baseline to end of the study was observed in the COPD Self-Efficacy Scale total score (P<.001) and domain scores (P<.001 for each domain). In total, 35.1% (n=27) of participants improved by at least 1 category of change on the 5-point Modified Medical Research Council dyspnea scale from baseline to week 24. Conclusions: This study confirmed the feasibility of using a remote model of care delivery to support people living with COPD. The insights gained in this study have allowed for further refinement and personalization of the Wellinks care model. Findings related to the combined use of technology and personal care delivery should be considered by others developing remote disease management tools. Trial Registration: ClinicalTrials.gov NCT05259280; https://clinicaltrials.gov/ct2/show/NCT05259280

24 March 2023 in JMIR Preprints
Verified
Preprint
Open access
KPKerri A Pierz
Kerri A Pierz
NLNicholas Locantore
Nicholas Locantore
GMGretchen McCreary
Gretchen McCreary
RCRobert J Calvey
Robert J Calvey
NHNickole Hackney
Nickole Hackney
JYJulie Yates
Julie Yates
BACKGROUND Wellinks is a remote disease management solution that provides novel chronic obstructive pulmonary disease (COPD) care delivery. OBJECTIVE This study evaluated the satisfaction, engagement, and clinical outcomes of Wellinks participants. This study also investigated the cadence of health coaching for patients with COPD. METHODS A 24-week interventional study was conducted by Wellinks and the COPD Foundation in 2022. Adults with COPD were recruited by the COPD Foundation in the United States and determined to be eligible if they had phone and internet access, owned a smartphone, and were not currently participating in pulmonary rehabilitation. All study participants provided written informed consent. The Wellinks solution included remote health coaching, pulmonary rehabilitation, and group education; participants were provided the Wellinks app and smart spirometry and pulse oximetry devices. Participants were offered 6 coaching sessions in the first 12 weeks. For the second 12-week period, participants either reduced frequency or discontinued coaching; all other components of the Wellinks solution remained unchanged. The COPD Self-Efficacy Scale, Modified Medical Research Council dyspnea scale, pulmonary function, pulse oximetry, and patient-reported healthcare resource utilization were the clinical outcome measures. Nonclinical outcomes included engagement and satisfaction with Wellinks and net promoter score. RESULTS In total, 141 adults consented and completed Wellinks onboarding; 84.4% (n=119) of whom remained engaged throughout the 24-week study. Participants had a mean age of 70 (SD 7.8; range 48-88) years, and 55.7% (n=78) were female. Most participants (n=119, 84.4%) completed all 6 coaching sessions during the first 12-week period. Compliance with spirometer and pulse oximeter use was 82.3% and 89.4%, respectively, at week 1 but waned over the study period to 8.5% and 9.2%, respectively, at the end of the study. Participants indicated a high degree of satisfaction with Wellinks, with 95.5% (n=85) and 91% (n=81) of participants indicating that they agreed or strongly agreed that the educational content and health coaching, respectively, were valuable. At the end of the study, the net promoter score was +64 and +55 in the coaching continuation and discontinuation arms, respectively. A significant improvement from baseline to end of the study was observed in the COPD Self-Efficacy Scale total score (P<.001) and domain scores (P<.001 for each domain). In total, 35.1% (n=27) of participants improved by at least 1 category of change on the 5-point Modified Medical Research Council dyspnea scale from baseline to week 24. CONCLUSIONS This study confirmed the feasibility of using a remote model of care delivery to support people living with COPD. The insights gained in this study have allowed for further refinement and personalization of the Wellinks care model. Findings related to the combined use of technology and personal care delivery should be considered by others developing remote disease management tools. CLINICALTRIAL ClinicalTrials.gov NCT05259280; https://clinicaltrials.gov/ct2/show/NCT05259280